mirror of
				https://github.com/msberends/AMR.git
				synced 2025-10-31 00:48:29 +01:00 
			
		
		
		
	Built site for AMR@2.1.1.9195: 9aab129
				
					
				
			This commit is contained in:
		| @@ -9,7 +9,7 @@ Adhering to previously described approaches (see Source) and especially the Baye | ||||
|  | ||||
|     <a class="navbar-brand me-2" href="../index.html">AMR (for R)</a> | ||||
|  | ||||
|     <small class="nav-text text-muted me-auto" data-bs-toggle="tooltip" data-bs-placement="bottom" title="">2.1.1.9192</small> | ||||
|     <small class="nav-text text-muted me-auto" data-bs-toggle="tooltip" data-bs-placement="bottom" title="">2.1.1.9195</small> | ||||
|  | ||||
|  | ||||
|     <button class="navbar-toggler" type="button" data-bs-toggle="collapse" data-bs-target="#navbar" aria-controls="navbar" aria-expanded="false" aria-label="Toggle navigation"> | ||||
| @@ -561,9 +561,9 @@ $$p_i = \frac{x_i}{\sum_{j=1}^K x_j}$$</p> | ||||
| <span class="r-out co"><span class="r-pr">#></span> <span style="color: #949494;"># An Antibiogram (WISCA / 95% CI): 3 × 4</span></span> | ||||
| <span class="r-out co"><span class="r-pr">#></span>   `Syndromic Group` `Piperacillin/tazobactam` Piperacillin/tazobactam + Gentam…¹</span> | ||||
| <span class="r-out co"><span class="r-pr">#></span>   <span style="color: #949494; font-style: italic;"><chr></span>             <span style="color: #949494; font-style: italic;"><chr></span>                     <span style="color: #949494; font-style: italic;"><chr></span>                             </span> | ||||
| <span class="r-out co"><span class="r-pr">#></span> <span style="color: #BCBCBC;">1</span> Clinical          76.1% (59.9-88.3%)        94.9% (85.2-99.2%)                </span> | ||||
| <span class="r-out co"><span class="r-pr">#></span> <span style="color: #BCBCBC;">2</span> ICU               60.3% (42.7-78.9%)        90.9% (77.4-98.1%)                </span> | ||||
| <span class="r-out co"><span class="r-pr">#></span> <span style="color: #BCBCBC;">3</span> Outpatient        67.2% (39-92%)            90% (68.6-99.4%)                  </span> | ||||
| <span class="r-out co"><span class="r-pr">#></span> <span style="color: #BCBCBC;">1</span> Clinical          76.2% (59.9-88.6%)        94.9% (85.2-99.2%)                </span> | ||||
| <span class="r-out co"><span class="r-pr">#></span> <span style="color: #BCBCBC;">2</span> ICU               60.3% (42.8-78.9%)        90.9% (77.4-98.1%)                </span> | ||||
| <span class="r-out co"><span class="r-pr">#></span> <span style="color: #BCBCBC;">3</span> Outpatient        67.2% (39-92%)            89.9% (68.6-99.4%)                </span> | ||||
| <span class="r-out co"><span class="r-pr">#></span> <span style="color: #949494;"># ℹ abbreviated name: ¹`Piperacillin/tazobactam + Gentamicin`</span></span> | ||||
| <span class="r-out co"><span class="r-pr">#></span> <span style="color: #949494;"># ℹ 1 more variable: `Piperacillin/tazobactam + Tobramycin` <chr></span></span> | ||||
| <span class="r-out co"><span class="r-pr">#></span> <span style="color: #949494;"># Use `ggplot2::autoplot()` or base R `plot()` to create a plot of this antibiogram,</span></span> | ||||
| @@ -588,8 +588,8 @@ $$p_i = \frac{x_i}{\sum_{j=1}^K x_j}$$</p> | ||||
| <span class="r-out co"><span class="r-pr">#></span> </span> | ||||
| <span class="r-out co"><span class="r-pr">#></span> |Syndromic Group |Piperacillin/tazobactam |</span> | ||||
| <span class="r-out co"><span class="r-pr">#></span> |:---------------|:-----------------------|</span> | ||||
| <span class="r-out co"><span class="r-pr">#></span> |Clinical        |76% (60-88.7%)          |</span> | ||||
| <span class="r-out co"><span class="r-pr">#></span> |ICU             |59.8% (40.7-80%)        |</span> | ||||
| <span class="r-out co"><span class="r-pr">#></span> |Clinical        |76% (60-88.6%)          |</span> | ||||
| <span class="r-out co"><span class="r-pr">#></span> |ICU             |59.8% (40.7-80.1%)      |</span> | ||||
| <span class="r-out co"><span class="r-pr">#></span> |Outpatient      |66.2% (38.1-91.3%)      |</span> | ||||
| <span class="r-in"><span></span></span> | ||||
| <span class="r-in"><span></span></span> | ||||
|   | ||||
		Reference in New Issue
	
	Block a user